GSK plc 6-K, filed Aug 24, 2022
GSK plc (GSK)
6-K
2022-08-24
For: 2022-08-24
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on August 24, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of August 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 24 August 2022, London UK - LSE announcement
GSK Board changes
●
Elizabeth
(Liz) McKee Anderson to join the Board as Non-Executive
Director
●
Appointment
follows announcement that Dr Laurie Glimcher will retire from the
Board in October 2022
GSK plc (LSE/NYSE: GSK) has today announced that Elizabeth (Liz)
McKee Anderson will join the Board of the Company as a
Non-Executive Director with effect from 1 September
2022.
Liz brings significant experience in commercial biopharmaceuticals
and is a seasoned biotech board member. She previously served as
Worldwide Vice President and commercial leader in infectious
diseases and vaccines and also for immunology and oncology at
Janssen Pharmaceuticals, and as Vice President and General Manager
at Wyeth Vaccines. Liz is currently a Board member of; BioMarin
Pharmaceuticals, Revolution Medicines, Inc., Insmed, Inc., and Aro
Biotherapeutics Company. She was also previously a Board member of
Bavarian Nordic A/S and of Huntsworth Plc. Liz also serves on the
Board of Trustees of The Wistar Institute, a leading biomedical
research organisation in the US.
Liz's appointment follows the announcement in July 2022, that Dr
Laurie Glimcher has advised the Company of her intention to retire
from the Board on 13 October 2022 after over 5 years as a
Non-Executive Director and designated Scientific and Medical
Expert.
Commenting on the changes, Sir Jonathan Symonds,
Chair of GSK, said: "I
would like to express my sincere thanks to Laurie for her excellent
contribution and commitment to GSK over a number of years. Through
her expertise in scientific and medical innovation, and public
health, Laurie has played a central role in the development of
GSK's current strategy and successful transition to a focused
biopharma company. We wish her well for the
future."
"I am delighted to welcome Liz to GSK. Her significant experience
in commercial biopharmaceuticals, both operationally and at Board
level, as well as her deep understanding of the biotechnology
sector will be invaluable to GSK as we begin our next chapter as a
100% focused biopharma company."
Notes:
|
|
1.
The appointment of Elizabeth McKee Anderson was made by the Board
on the recommendation of the Nominations & Corporate Governance
Committee. The Committee conducted an extensive search and
selection process for this appointment, using an external search
firm, which is a signatory of the Voluntary Code of Conduct for
Executive Search Firms. The external search firm provided a
diverse list of candidates who were approached, evaluated and
interviewed, against an agreed set of criteria aligned to the
Board's target skills matrix.
|
|
|
2.
The Board has determined that Elizabeth McKee Anderson is an
independent Non-Executive Director in accordance with the UK
Corporate Governance Code.
|
|
|
3.
Ms McKee Anderson will receive the standard basic fee for a
Non-Executive Director of £95,000 per annum. (Ms McKee
Anderson will be required to build towards a share ownership
requirement of GSK shares in accordance with the Company's
shareholder approved Non-Executive remuneration
policy).
|
|
|
4.
Ms McKee Anderson has also been appointed a member of the Audit
& Risk and Remuneration committees.
|
|
|
5. Ms
McKee Anderson does not have a service contract. She has a letter
of appointment which may be viewed by contacting the Company
Secretary at the Company's registered office.
|
|
|
6.
There are no further disclosures to be made in respect of Ms McKee
Anderson's appointment under Listing Rule 9.6.13R.
|
|
|
7. As of 1 September 2022 the Board of GSK will
comprise:
|
|
Sir Jonathan
Symonds
|
Non-Executive
Chair
|
|
Emma
Walmsley
|
Chief Executive
Officer
|
|
Iain
Mackay
|
Chief Financial
Officer
|
|
Charles
Bancroft
|
Senior Independent
Non-Executive Director
|
|
Elizabeth McKee
Anderson
|
Independent
Non-Executive Director
|
|
Dr Hal
Barron
|
Non-Executive
Director
|
|
Dr Anne
Beal
|
Independent
Non-Executive Director
|
|
Dr Hal
Dietz
|
Independent
Non-Executive Director
|
|
Dr Jesse
Goodman
|
Independent
Non-Executive Director
|
|
Dr Laurie
Glimcher*
|
Independent
Non-Executive Director
|
|
Urs
Rohner
|
Independent
Non-Executive Director
|
|
Dr Vishal
Sikka
|
Independent
Non-Executive Director
|
*Retires from the Board
on 13 October 2022.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company
|
GSK enquiries
|
|
|
|
|
Media:
|
Simon Moore
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Alison Hunt
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
Cautionary
statement regarding forward-looking statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered
in England & Wales:
No.
3888792
Registered
Office:
980 Great West
Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: August
24, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|